Company profile
ROCKET PHARMACEUTICALS, INC.
NASDAQ:RCKTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| KRESLADI | approved | $0.0MQ2 2026 | 2 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03812263 | phase1_2 | completed | 2019-08-30 | 2023-09-12 | Rocket Pharmaceuticals Inc. | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
| NCT03814408 | phase1 | unknown | 2019-01-11 | 2020-12-01 | Rocket Pharmaceuticals Inc. | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A |
| NCT06092034 | phase2 | recruiting | 2023-09-05 | 2028-06-01 | Rocket Pharmaceuticals Inc. | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease |
| NCT03825783 | phase1 | withdrawn | 2019-04-15 | 2021-10-01 | Rocket Pharmaceuticals Inc. | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
| NCT07137338 | phase1 | recruiting | 2026-04-17 | 2029-06-01 | Rocket Pharmaceuticals Inc. | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125806 | 2026-03-26 | BLA | ROCKET PHARMACEUTICALS INC | |||||
Loading… | ||||||||